8-K current report · filed Jul 22, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K Current Report: July 22, 2026

Item EX-99.1Item 2.02SUPN overview

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on July 22, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Supernus schedules Q2 2026 results release after market close on August 4, 2026.

SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Supernus schedules Q2 2026 results release after market close on August 4, 2026
  • Management conference call and webcast at 4:30 p.m. ET on August 4, 2026
  • Event provides investors the next scheduled update on financial performance and business developments

Item EX-99.1 · Exhibit EX-99.1

  • Second-quarter 2026 results scheduled for August 4, 2026, after market close
  • CEO Jack Khattar and CFO Tim Dec hosting investor conference call at 4:30 p.m. ET
  • Event provides upcoming readout on CNS product performance, profitability, pipeline progress, and corporate strategy
  • Webcast replay available on Supernus’ Investor Relations website for 60 days

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings

Get the next SUPN 8-K as it lands

Follow SUPN for push alerts, or ask the research agent what this filing means.